TOMMANNUUTTILIMINATIONUS009862693B2 (12 ) United States Patent ( 10 ) Patent No

Total Page:16

File Type:pdf, Size:1020Kb

TOMMANNUUTTILIMINATIONUS009862693B2 (12 ) United States Patent ( 10 ) Patent No TOMMANNUUTTILIMINATIONUS009862693B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 , 862, 693 B2 Pietras et al. (45 ) Date of Patent : Jan . 9 , 2018 ( 54 ) COMPOUNDS AND METHODS OF ( 56 ) References Cited TREATING CANCER U . S . PATENT DOCUMENTS (71 ) Applicant : The Regents of the University of 4 , 574 ,123 A * 3 / 1986 Edwards . .. .. C07C 279/ 28 California , Oakland , CA (US ) 162 / 161 4 , 861, 760 A 8 / 1989 Mazuel et al. ( 72 ) Inventors : Richard J . Pietras , Los Angeles , CA 4 ,911 , 920 A 3 / 1990 Jani et al . (US ) ; Michael E . Jung, Los Angeles , 5 ,212 , 162 A 5 / 1993 Missel et al. CA (US ) ; Diana C . Marquez -Garban , 5 , 403 , 841 A 4 / 1995 Lang et al . 6 ,699 ,989 B1 * 3 / 2004 Shetty CO7D 215 / 56 Los Angeles, CA (US ) ; Gang Deng, 540 /474 Los Angeles, CA (US ) 7 , 285 ,681 B2 * 10 /2007 Moinet .. .. .. CO7D 295/ 215 564 /233 ( 73 ) Assignee : The Regents of the University of 7 ,671 , 019 B2 * 3 /2010 Tobia A61K 8 /44 California , Oaklnad , CA (US ) 514 / 1 . 1 8 , 853, 259 B2 10 /2014 Mylari Subject to any disclaimer, the term of this 2010 / 0087544 A1 4 / 2010 Kim et al. ( * ) Notice : 2011 /0196015 A1 8 / 2011 Kim et al . patent is extended or adjusted under 35 2011 / 0207810 Al 8 / 2011 Kim et al . U . S . C . 154 (b ) by 40 days. 2015 /0126518 Al 5 /2015 Kim et al . ( 21) Appl . No. : 14 /566 ,055 FOREIGN PATENT DOCUMENTS ( 22 ) Filed : Dec . 10 , 2014 WO WO - 96 /05309 A2 2 / 1996 WO WO - 96 /05309 A3 2 / 1996 (65 ) Prior Publication Data WO WO - 2011 /083998 A2 7 / 2011 WO WO - 2011 /083998 A3 7 / 2011 US 2015 /0158832 A1 Jun . 11, 2015 WO WO - 2011 / 147528 Al 12 / 2011 Related U . S . Application Data OTHER PUBLICATIONS (63 ) Continuation of application No . CAPLUS on STN , accession No . 2010 :923694 , Abstract of PCT/ US2013 /045250 , filed on Jun . 11, 2013 . CN101781273 Jul. 21 , 2010 . * Registry No . 793641 -52 - 8 , CAPLUS on STN , Dec . 7 , 2004. * (60 ) Provisional application No . 61/ 658 ,238 , filed on Jun . Alimova I . N . et al. (Mar . 15 , 2009) . “ Metformin inhibits breast 11 , 2012 . cancer cell growth , colony formation and induces cell cycle arrest in vitro , ” Cell Cycle 8 ( 6 ) : 909 - 915 . ( 51 ) Int. Cl. Berstein , L . M . ( Aug. 2010 ) . “ Modern approach to metabolic reha CO7D 295 /215 ( 2006 .01 ) bilitation of cancer patients : biguanides ( phenformin and CO7D 203 /20 ( 2006 .01 ) metformin ) and beyond ,” Future Oncol 6 ( 8 ) : 1313 - 23 . CO7D 211 / 16 ( 2006 . 01 ) Carey , L . A . et al . ( Jun . 7 , 2006 ). “ Race , breast cancer subtypes , and survival in the Carolina Breast Cancer Study ," JAMA 295 (21 ) : 2492 C07D 213 / 78 ( 2006 .01 ) 2502 . C07D 239 /28 ( 2006 . 01 ) Currie C . J . et al. ( Feb . 2012 , e - published Jan . 20 , 2012 ) . " Mortality C07D 401/ 12 ( 2006 . 01 ) after incident cancer in people with and without type 2 diabetes : A61K 31/ 155 ( 2006 . 01 ) impact of metformin on survival, ” Diabetes Care 35 ( 2 ): 299 - 304 . C07C 279 / 26 ( 2006 . 01 ) Dowling , R . J . et al . (Apr . 6 , 2011 ) . “ Understanding the benefit of metformin use in cancer treatment, ” BMC Med : 9 : 33 . A61K 31/ 4025 ( 2006 . 01 ) Dilman , V . M . et al . ( 1982 ) . “ Metabolic immunodepression and A61K 31 /445 ( 2006 .01 ) metabolic immunotherapy : an attempt of improvement in immuno A61K 31/ 4545 ( 2006 .01 ) logic response in breast cancer patients by correction of metabolic A61K 31/ 496 ( 2006 .01 ) disturbances , ” Oncology 39 ( 1 ) : 13 - 19 . A61K 31 /5377 ( 2006 .01 ) Evans , J . M . et al . (Jun . 4 , 2005 ) . " Metformin and reduced risk of cancer in diabetic patients , ” BMJ 330 ( 7503 ) :1304 - 1305 . C07C 279 / 22 ( 2006 .01 ) Foulkes, W . D . et al . (Nov . 11, 2010 ) . " Triple -negative breast can (52 ) U . S . CI. cer, " N Engl J Med . 363 ( 20 ) : 1938 - 1948 CPC . .. .. .. CO7D 295 /215 ( 2013 .01 ) ; A61K 31 / 155 International Search Report dated Nov . 1 , 2013 , for PCT Applica ( 2013 .01 ) ; A61K 31 /4025 ( 2013 .01 ) ; A61K tion No . PCT /US2013 /045250 , filed on Jun . 11 , 2013 , 4 pages . 31 /445 ( 2013 . 01 ) ; A61K 31/ 4545 ( 2013 .01 ) ; James , J. W . et al . (Sep . 1968 ) . “ The synthesis of some heterocyclic A61K 31/ 496 ( 2013 . 01 ) ; A61K 31 /5377 derivatives of biguanide with antibacterial activity , " J Med Chem (2013 . 01 ) ; C07C 279 / 22 ( 2013 . 01) ; C07C 11 ( 5 ): 942 - 945 . 279 / 26 ( 2013 .01 ) ; C07D 203 /20 ( 2013 . 01 ) ; (Continued ) CO7D 211/ 16 (2013 .01 ) ; C07D 213/ 78 Primary Examiner — Rebecca L Anderson ( 2013. 01 ) ; C07D 239 / 28 (2013 .01 ) ; C07D ( 74 ) Attorney , Agent, or Firm - Zachary L . Terranova ; 401 / 12 (2013 .01 ) Mintz , Levin , Cohn , Ferris , Glovsky and Popeo , P . C . ( 58 ) Field of Classification Search (57 ) ABSTRACT CPC .. .. CO7D 295 /215 ; C07D 203 / 20 ; CO7D Presented herein inter alia are novel compounds and meth 211710211 / 16 ; COLCO7D 213 / 78 ; CO7D 239 /28 ; CO7D 401/ 12 ods of using the same for the treatment of cancers . See application file for complete search history. 7 Claims, 10 Drawing Sheets US 9 , 862, 693 B2 Page 2 References Cited Kelarev, V . I . et al . (Sep . 1993 ) . “ Synthesis and properties of (56 ) derivatives of sym - triazines. 11 . Synthesis of 2 - amino - sym - triazines containing alkyl radicals , ” Chemistry of Heterocyclic Compounds OTHER PUBLICATIONS 29 ( 9 ) : 1087 - 1092 . Jiralerspong , S . et al. ( Jul. 10 , 2009 , e - published Jun . 1 , 2009 ) . Koh , M . et al. ( Apr. 2013 , e -published Feb . 22 , 2013 ) . “ A novel metformin derivative , HL010183 , inhibits proliferation and inva “ Metformin and pathologic complete responses to neoadjuvant sion of triple -negative breast cancer cells ,” Bioorg Med Chem chemotherapy in diabetic patients with breast cancer ,” J Clin Oncol. 21( 8 ) : 2305 - 2313 . 27 (20 ) :3297 -3302 . Liu , B . et al. ( Jul. 1 , 2009 , e -published Jul. 21, 2009 ) . " Metformin Jiralerspong, S . et al . ( Sep . 1 , 2009 ) . " Expanding the arsenal : induces unique biological and molecular responses in triple negative metformin for the treatment of triple -negative breast cancer ? ” Cell breast cancer cells , " Cell Cycle 8 ( 13 ) :2031 - 2040 . Cycle : 8 ( 17 ) : 2681 - 2684 . Nagasaka , H . et al . Yuki Gosei Kagaku Kyokaishi ( 1967 ) . Kihara , Y . et al. ( 1990 ) . Journal of Heterocyclic Chemistry 27 : 1213 25 ( 9 ) :802 -807 . (English translation of Abstract only ) . 1216 . Sahra , I. B . et al . (May 2010 , e - published May 4 , 2010 ) . “ Metformin Kelarev, V . I. et al . (May 1988 ). “ Synthesis and properties of in cancer therapy : a new perspective for an old antidiabetic drug ? ” sym - triazine derivatives . 7 . Synthesis of pyridyl - substituted Mol Cancer Ther 9 ( 5 ) : 1092 - 1099 . 2 -amino - and 2 , 4 -diamino - sym -triazines , ” Chemistry of Heterocy Taubes, G . ( Jan . 6 , 2012 ) . " Cancer research . Unraveling the obesity clic Compounds 24 ( 5 ) :550 - 555 . cancer connection ,” Science 335 (6064 ): 28 , 30 - 32 . Kelarev , V . I. et al. (Sep . 1992) . " Synthesis and properties of Written Opinion dated Nov. 1 , 2013 , for PCT Application No . sym - triazine derivatives 9 . Synthesis of 2 - amino - and 2 , 4 -diamino PCT/ US2013 /045250 , filed on Jun . 11, 2013 , 7 pages. sym - triazines containing furan fragments ,” Chemistry of Heterocy clic Compounds 28 ( 9 ) : 1060 - 1065 . * cited by examiner U . S . Patent Jan. 9 , 2018 Sheet 1 0f10 US 9 , 862 , 693 B2 FIC , 1 ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ?3 ?? ? ? . 282 ??????etw ? ?????? ? ? ? ? ? ? ? ?? ? ?? ? ? ? ? ? ? ? ? ? ? ? ? ???????????? 8944???????V9?????????} 8 ??????????????????? ????? ????3 %8385 ? ???i " " ? ; : ? ? ?? •••H•• ? ? ? ? ? ? , : 383 ; ????????????????????????????????????????????????????????????? ? 8_ 8A % ? ? 8_ ? ??? w & gt ; ? ? ?? ? ffx ?( ???????????????????????????????????????e 8_ ? { ACFT ???????????????????????????? e ????????????????????? cont _com = inopinion f { Y388 U . S . Patent Jan . 9 , 2018 Sheet 2 of 10 US 9, 862 , 693 B2 FIG . 2A MANNNNNNN N NNNNNNNN =-= - = - = -= - = =-= -= - ?????????????STYLE =-= - - - = ??????? whithinninnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnitinin ?? , “ ? ??????? ? ?? | FIG . 2B FYMVIT -AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMAHAMMMMMMMMMMMMMMMMMMMMMP MMMMMMMMMMMMMMMMMM www .www . www . riversinaimagaine .www .www wwwronmentNows… …… …… … …… … … … …… … Newmwww “ ? AirHANNAHAH ????????????????????? ManasoniaMainstationa IPH55974???????????????????AHAN ????????? ????? ??????, ? ????????????????????????? HANN U . S . Patent Jan . 9 , 2018 Sheet 3 of 10 US 9 , 862 ,693 B2 FIG . 2C * 3000 * 30002 w W10003 (QUODWuongelafjord 30004 NVNV. w jg005 * * * NENOVSMANN page ON WWWWWWWWWWWWWWWWWWWWWHCC1937 FIG . 2D theBE Pe V0002 waganiningi n isinesuivalenten imon 0005 (PQXudoX)dodelajoidja . n wwwwwwwwwwwwwwww HCC1806 wy 2 BV U . S . Patent Jan . 9 , 2018 Sheet 4 of 10 US 9 , 862 ,693 B2 FIG . 3A - - - - - - * * * * ** * * * * * X60 Segweiserovi - - ???????????????????????????????????????????m - lozo3xodisada - optoutoni se sitreba primeraintegrado * * * * * * * * * * * * * * * * * * * * A549 00 .. 1 FIG . 3B wwwwwww wwwww CelProliferation(control) trandapihtimentointer spretrgarnir eru potapetate * * * 0004 operas stranurecorded wwvini winniiiiiiiiiiiiiiiiiiiiiinnin MDAMB435 WWWWWWWWWWWWWWWWWWWWWWWWWW 110 . 5 U . S . Patent Jan . 9 , 2018 Sheet Sof 10 US 9, 862 , 693 B2 FIG. 44 … ?MAMAWAIWANNINAWAIWANNNNNNNNNNNNNNNNNNINeeweller trif; firsterferrary Ferrer Firsterferrary Ferrer , :: …: : : … … .… … :: … … * , … ** * * * *, * * , ? … “ ? ???? MAMAMAHANNERY ?3?????
Recommended publications
  • Identification of Chalcone Derivatives As Putative Non-Steroidal Aromatase
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Online Publishing @ NISCAIR Indian Journal of Chemistry Vol. 59B, February 2020, pp. 283-293 Identification of chalcone derivatives as putative non-steroidal aromatase inhibitors potentially useful against breast cancer by molecular docking and ADME prediction Umang Shah*a, Samir Patela, Mehul Patela, Karan Gandhia & Ashish Patelb a Department of Pharmaceutical Chemistry, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa 388 421, India b Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Parul University, P.O. Limda 391 760, Dist. Vadodara, India E-mail: [email protected] Received 30 August 2019; accepted (revised) 16 October 2019 Aromatase is an influential target to overcome estrogen receptor positive breast cancer, as the enzyme is responsible for conversion of androstenedione to estrone, a promising drug target for therapeutic management of breast cancer. Chalcones are prominent biosynthetic compounds and parent candidate for the synthesis of heterocycles with diversified biological activities. The prime objective of the present study is to evaluate the binding interaction of 2-hydroxyphenyl- prop-2-en-1- one (1A-1X), 2-hydroxy-4-methoxyphenyl- prop-2-en-1-one (3A-3X), 2,4-dihydroxyphenyl- prop-2-en-1-one (9A-9X) and 1-hydroxynaphthalen-2-yl-prop-2-en-1-one (5A-5X) derivatives with aromatase enzyme by molecular docking study and also check their ADME properties by maestro suit. The designed chalcones derivatives have been docked against our target protein with PDB id 3S7S retrieved from the protein data bank, whereas exemestane has been taken as the positive control.
    [Show full text]
  • Prospects for NK Cell Therapy of Sarcoma
    cancers Review Prospects for NK Cell Therapy of Sarcoma Mieszko Lachota 1 , Marianna Vincenti 2 , Magdalena Winiarska 3, Kjetil Boye 4 , Radosław Zago˙zd˙zon 5,* and Karl-Johan Malmberg 2,6,* 1 Department of Clinical Immunology, Doctoral School, Medical University of Warsaw, 02-006 Warsaw, Poland; [email protected] 2 Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 3 Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; [email protected] 4 Department of Oncology, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 5 Department of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland 6 Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 86 Stockholm, Sweden * Correspondence: [email protected] (R.Z.); [email protected] (K.-J.M.) Received: 15 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Sarcomas are a group of aggressive tumors originating from mesenchymal tissues. Patients with advanced disease have poor prognosis due to the ineffectiveness of current treatment protocols. A subset of lymphocytes called natural killer (NK) cells is capable of effective surveillance and clearance of sarcomas, constituting a promising tool for immunotherapeutic treatment. However, sarcomas can cause impairment in NK cell function, associated with enhanced tumor growth and dissemination. In this review, we discuss the molecular mechanisms of sarcoma-mediated suppression of NK cells and their implications for the design of novel NK cell-based immunotherapies against sarcoma.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • The Emerging Role of Paclitaxel in Breast Cancer Therapy1
    Vol. 1, 247-256, March 1995 Clinical Cancer Research 247 Minireview The Emerging Role of Paclitaxel in Breast Cancer Therapy1 Andrew D. Seidman2 overexpressing subline of MCF-7 cells appears to result in the Breast and Gynecological Oncology Service, Memorial Sloan- development of 4.4-fold less resistance (6). Furthermore, in Kettering Cancer Center, New York, New York 10021 paclitaxel-resistant cells, the ratio of soluble to polymerized tubulin is greater than that observed in sensitive cells (7). Introduction Ongoing investigation should clarify the relationship between Multiple chemotherapeutic agents and regimens exist with tubulin alterations and resistance to taxanes. documented antitumor activity against breast cancer; however, In parallel with the development of clinical trials of paclitaxel- less than one in five patients with stage IV breast cancer are alive based combination regimens, in vivo and in vitro studies have 5 years from the first detection of distant metastases (1). Although examined combinations for cytotoxicity in several systems. In vitro improved response proportions have been observed, overall sur- studies in human MCF-7 breast carcinoma cells exposed to a LD vival for patients with metastatic breast cancer has not been sig- of paclitaxel for 24 h followed by a 1-h incubation with varying nificantly improved by the progress of the past three decades. Furthermore, despite the proven magnitude of benefit of adjuvant concentrations of doxorubicin showed less than additive cytotox- icity for the combination of paclitaxel and doxorubicin (8). On the systemic therapy in reducing the risk of recurrence (2), a significant fraction of patients with early stage breast cancer still will relapse other hand, when an AlT cell viability assay was used, others have and ultimately die of metastatic disease.
    [Show full text]
  • Differences Between the Non-Steroidal Aromatase Inhibitors Anastrozole and Letrozole – of Clinical Importance?
    British Journal of Cancer (2011) 104, 1059 – 1066 & 2011 Cancer Research UK All rights reserved 0007 – 0920/11 www.bjcancer.com Minireview Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance? ,1 J Geisler* 1 Institute of Clinical Medicine, University of Oslo, Faculty Division at Akershus University Hospital, Sykehusveien 27, Lørenskog N-1478, Norway Aromatase inhibition is the gold standard for treatment of early and advanced breast cancer in postmenopausal women suffering from an estrogen receptor-positive disease. The currently established group of anti-aromatase compounds comprises two reversible aromatase inhibitors (anastrozole and letrozole) and on the other hand, the irreversible aromatase inactivator exemestane. Although exemestane is the only widely used aromatase inactivator at this stage, physicians very often have to choose between either anastrozole or letrozole in general practice. These third-generation aromatase inhibitors (letrozole/Femara (Novartis Pharmaceuticals, Basel, Switzerland) and anastrozole/Arimidex (AstraZeneca, Pharmaceuticals, Macclesfield, Cheshire, UK)), have recently demonstrated superior efficacy compared with tamoxifen as initial therapy for early breast cancer improving disease-free survival. However, although anastrozole and letrozole belong to the same pharmacological class of agents (triazoles), an increasing body of evidence suggests that these aromatase inhibitors are not equipotent when given in the clinically established doses. Preclinical and clinical evidence indicates distinct pharmacological profiles. Thus, this review focuses on the differences between the non-steroidal aromatase inhibitors allowing physicians to choose between these compounds based on scientific evidence. Although we are waiting for the important results of a still ongoing head-to-head comparison in patients with early breast cancer at high risk for relapse (Femara Anastrozole Clinical Evaluation trial; ‘FACE-trial’), clinicians have to make their choices today.
    [Show full text]
  • WO 2017/112768 Al 29 June 2017 (29.06.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/112768 Al 29 June 2017 (29.06.2017) P O P C T (51) International Patent Classification: Delaware 19707 (US). ZHUANG, Linghang; 3135 Fox C07D 471/10 (2006.01) A61K 31/47 (2006.01) Drive, Chalfont, Pennsylvania 18914 (US). C07D 487/10 (2006.01) A61K 31/519 (2006.01) (74) Agents: DAVEY, PH.D., Evan A. et al; Fish & Richard C07D 495/04 (2006.01) A61P 35/02 (2006.01) son P.C., P.O. Box 1022, Minneapolis, Minnesota 55440- C07D 513/04 (2006.01) 1022 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US20 16/0680 16 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 2 1 December 2016 (21 .12.2016) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (26) Publication Language: English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (30) Priority Data: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 62/270,973 22 December 201 5 (22. 12.2015) US RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (71) Applicant: VITAE PHARMACEUTICALS, INC.
    [Show full text]
  • Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy † EVAN R
    Aromatase and Its Inhibitors: Significance for Breast Cancer Therapy † EVAN R. SIMPSON* AND MITCH DOWSETT *Prince Henry’s Institute of Medical Research, Monash Medical Centre, Clayton, Victoria 3168, Australia; †Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom ABSTRACT Endocrine adjuvant therapy for breast cancer in recent years has focussed primarily on the use of tamoxifen to inhibit the action of estrogen in the breast. The use of aromatase inhibitors has found much less favor due to poor efficacy and unsustainable side effects. Now, however, the situation is changing rapidly with the introduction of the so-called phase III inhibitors, which display high affinity and specificity towards aromatase. These compounds have been tested in a number of clinical settings and, almost without exception, are proving to be more effective than tamoxifen. They are being approved as first-line therapy for elderly women with advanced disease. In the future, they may well be used not only to treat young, postmenopausal women with early-onset disease but also in the chemoprevention setting. However, since these compounds inhibit the catalytic activity of aromatase, in principle, they will inhibit estrogen biosynthesis in every tissue location of aromatase, leading to fears of bone loss and possibly loss of cognitive function in these younger women. The concept of tissue-specific inhibition of aromatase expression is made possible by the fact that, in postmenopausal women when the ovaries cease to produce estrogen, estrogen functions primarily as a local paracrine and intracrine factor. Furthermore, due to the unique organization of tissue-specific promoters, regulation in each tissue site of expression is controlled by a unique set of regulatory factors.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,062,029 B2 Schadt Et Al
    USOO9062O29B2 (12) United States Patent (10) Patent No.: US 9,062,029 B2 Schadt et al. (45) Date of Patent: *Jun. 23, 2015 (54) PYRIMIDINYL PYRIDAZINONE 417/10 (2013.01); C07D 417/14 (2013.01); DERVATIVES C07D 451/06 (2013.01); C07D 453/02 (2013.01); A61 K3I/501 (2013.01); A61 K (71) Applicant: Merck Patent GmbH, Darmstadt (DE) 3 1/506 (2013.01); A61 K3I/5355 (2013.01): (72) Inventors: Oliver Schadt, Rodenbach (DE); Dieter A6IK3I/5377 (2013.01); A61K3I/55 Dorsch, Ober-Ramstadt (DE); Frank (2013.01); A61K 45/06 (2013.01) Stieber, Heidelberg (DE); Andree (58) Field of Classification Search Blaukat, Schriesheim (DE) CPC C07D 403/14: A61K31/506; A61K31/5377 USPC ................... 514/236.5, 252.02:544/123, 298 (73) Assignee: Merck Patent GmbH, Darmstadt (DE) See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 0 days. This patent is Subject to a terminal dis U.S. PATENT DOCUMENTS claimer. 6,242.461 Bl 6/2001 Goldstein 6,403,586 B1 6/2002 Ohkuchi et al. (21) Appl. No.: 14/149,110 8,071,593 B2 12/2011 Schadt et al. 8,173,653 B2 5, 2012 Dorsch et al. (22) Filed: Jan. 7, 2014 8,329,692 B2 12/2012 Schadt et al. 8,580,781 B2 * 1 1/2013 Dorsch et al. ............ 514,217.06 (65) Prior Publication Data 8,658,643 B2 * 2/2014 Schadt et al. .............. 514,236.5 2004/O152739 A1 8, 2004 Hanau US 2014/O128396 A1 May 8, 2014 2004/0259863 A1 12/2004 Eggenweiler et al.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub
    US 20090226431A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub. Date: Sep. 10, 2009 (54) TREATMENT OF CANCER AND OTHER Publication Classification DISEASES (51) Int. Cl. A 6LX 3/575 (2006.01) (76)76) InventorInventor: Nabilabil Habib,Habib. Beirut (LB(LB) C07J 9/00 (2006.01) Correspondence Address: A 6LX 39/395 (2006.01) 101 FEDERAL STREET A6IP 29/00 (2006.01) A6IP35/00 (2006.01) (21) Appl. No.: 12/085,892 A6IP37/00 (2006.01) 1-1. (52) U.S. Cl. ...................... 424/133.1:552/551; 514/182: (22) PCT Filed: Nov.30, 2006 514/171 (86). PCT No.: PCT/US2O06/045665 (57) ABSTRACT .."St. Mar. 6, 2009 The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3B.5C,6C.-triol), its production, its use, and to methods of treating neoplasms and other tumors as Related U.S. Application Data well as other diseases including hypercholesterolemia, (60) Provisional application No. 60/741,725, filed on Dec. autoimmune diseases, viral diseases (e.g., hepatitis B, hepa 2, 2005. titis C, or HIV), and diabetes. F2: . - 2 . : F2z "..., . Cz: ".. .. 2. , tie - . 2 2. , "Sphagoshgelin , , re Cls Phosphatidiglethanolamine * - 2 .- . t - r y ... CBs .. A . - . Patent Application Publication Sep. 10, 2009 Sheet 1 of 16 US 2009/0226431 A1 E. e'' . Phosphatidylcholine. " . Ez'.. C.2 . Phosphatidylserias. * . - A. z' C. w E. a...2 .". is 2 - - " - B 2. Sphingoshgelin . Cls Phosphatidglethanglamine Figure 1 Patent Application Publication Sep. 10, 2009 Sheet 2 of 16 US 2009/0226431 A1 Chile Phosphater Glycerol Phosphatidylcholine E.
    [Show full text]
  • Refined Preparation of 1α,3-Dipyrrolidino-Androsta-3,5-Diene-17-One, a Key Intermediate in the Exemestane Synthesis
    ORIGINAL ARTICLES Pharmaceutical Research Institute1; Faculty of Chemistry, University of Warsaw, Warsaw, Poland Refined preparation of 1␣,3-dipyrrolidino-androsta-3,5-diene-17-one, a key intermediate in the exemestane synthesis Ł. Kaczmarek 1, M. Cybulski 1, M. Kubiszewski 1,A.Les´ 1,2 Received February 3, 2012, accepted March 31, 2012 Prof. Andrzej Le´s, Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warsaw, Poland [email protected] Pharmazie 67: 899–905 (2012) doi: 10.1691/ph.2012.2025 A significant improvement of the patent route for exemestane synthesis has been achieved. The key inter- mediate 1␣,3-dipyrrolidino-androsta-3,5-diene-17-one (7) was obtained in a good yield and effectively used without further isolation in the next reaction step. The original analytical method for the identification and quantification of the substrate androsta-1,4-diene-3,17-dione (ADD, 6), intermediate 7 and 1-pyrrolidino- androsta-1,3,5-triene-17-one (9) impurity in the reaction mixture was applied. Due to the newly developed process, the economical synthesis of the final pharmaceutical product in a large scale was possible. In addition, the complete NMR characteristics of 7 was described for the first time. The experiments were also analyzed with the theoretical quantum mechanical density functional B3LYPcalculations for the energy outputs in model reactions. Based on these studies hypothetical routes of key intermediate (7) formation have been suggested. These predictions were consistent with the solutions of kinetic equations fitted to the experimental curves for time-dependence of three components of the reaction mixture. 1.
    [Show full text]
  • Thesis of Novel Anticancer Agents with Therapeutic Potential
    University of Bath PHD The synthesis of novel anticancer agents with therapeutic potential Ganeshapillai, Dharshini Award date: 2001 Awarding institution: University of Bath Link to publication Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 08. Oct. 2021 THE SYNTHESIS OF NOVEL ANTICANCER AGENTS WITH THERAPEUTIC POTENTIAL Submitted by Dharshini Ganeshapillai for the degree of Doctor of Philosophy of the University of Bath 2001 COPYRIGHT Attention is drawn to the fact that the copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without the prior written consent of the author.
    [Show full text]
  • Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: a Century-Long Story
    Review Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story Rand Naffouje 1, Punita Grover 1, Hongyang Yu 2,3, Arun Sendilnathan 1, Kara Wolfe 1,4, Nazanin Majd 5, Eric P. Smith 6, Koh Takeuchi 7, Toshiya Senda 2,3, Satoshi Kofuji 8 and Atsuo T. Sasaki 1,4,9,10,* 1 Division of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA; [email protected] (P.G.); [email protected] (A.S.); [email protected] (K.W.); [email protected] (A.T.S.) 2 Structural Biology Research Center, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tokyo 135-0063, Japan; [email protected] (H.Y.); [email protected] (T.S.) 3 Department of Accelerator Science, School of High Energy Accelerator Science, SOKENDAI (the Graduate University for Advanced Studies), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan 4 Department of Cancer Biology, University of Cincinnati College of Medicine, OH 45267, USA 5 Department of Neuro-oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA; [email protected] 6 Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA; [email protected] 7 Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Science and Technology, 2-3-26 Aomi, Koto, Tokyo 135-0063, Japan; [email protected] 8 Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan; [email protected] 9 Department of Neurosurgery, Brain Tumor Center at UC Gardner Neuroscience Institute, Cincinnati, OH 45267, USA 10 Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata 997-0052, Japan * Correspondence: [email protected] Received: 9 August 2019; Accepted: 2 September 2019; Published: 11 September 2019 Abstract: The purine nucleotides ATP and GTP are essential precursors to DNA and RNA synthesis and fundamental for energy metabolism.
    [Show full text]